Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. Academic Article uri icon

Overview

abstract

  • OBJECTIVES: Determine if cetuximab dose escalation to induce grade 2 rash correlates with anti-tumor activity and if sera-based markers could predict likelihood of response. METHODS: Patients with persistent/recurrent ovarian or primary peritoneal carcinoma received an initial dose of cetuximab 400 mg/m(2), then 250 mg/m(2) weekly for two 3-week cycles. Patients who had stable disease (SD) and

publication date

  • January 21, 2009

Research

keywords

  • Acneiform Eruptions
  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Neoplasm Recurrence, Local
  • Ovarian Neoplasms
  • Peritoneal Neoplasms

Identity

PubMed Central ID

  • PMC2741166

Scopus Document Identifier

  • 60749092998

Digital Object Identifier (DOI)

  • 10.1016/j.ygyno.2008.12.003

PubMed ID

  • 19162309

Additional Document Info

volume

  • 113

issue

  • 1